Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 121–144 of 145
GARM Clinic has added Klotho to its non-permanent gene therapy platform alongside Follistatin and VEGF, positioning itself as a clinical destination for early-stage longevity interventions. Klotho addresses age-related decline in the protein's natural production, targeting mitochondrial function, metabolic resilience, and systemic health markers that degrade with age.
Life Biosciences' ER-100, a cellular reprogramming therapy, entered FDA-cleared human trials in January 2026 for optic nerve disorders, marking the first regulatory authorization of a rejuvenation-based intervention. The trial structure and emergence of the Plausible Mechanism Pathway suggest regulatory willingness to advance age-reversal technologies through disease-specific endpoints, potentially accelerating clinical translation of cellular reprogramming across multiple organ systems.
Google's redesign of Fitbit into Google Health repositions wearables as a data platform rather than a subscription product, leveraging AI-powered coaching to interpret health signals for users. This shift threatens the business models of standalone wearable companies by commoditizing their core tracking functions within a larger software ecosystem.
Klothea Bio has initiated a Phase 1b trial of AKL003, an mRNA therapy designed to elevate circulating alpha klotho protein levels in healthy adults. The trial represents a direct approach to testing whether increased klotho—a protein associated with organ protection and repair across multiple physiological systems—can favorably shift biomarkers linked to human lifespan and biological age.
PDE5 inhibitors, established drugs for erectile dysfunction, are attracting early interest in longevity medicine for their capacity to improve vascular function and tissue resilience through nitric oxide signaling—not by targeting root causes of aging, but by supporting system performance under the stress of accumulated damage.
WHOOP has secured $575 million in Series G funding at a $10.1 billion valuation, positioning itself as a continuous health monitoring platform that translates physiological data into actionable guidance. The funding reflects investor confidence that longevity platforms embedding real-time health tracking into daily life can shift healthcare from reactive to proactive intervention.
Evolve Science has launched a peptide and longevity platform that differentiates itself through supply chain transparency and batch-level documentation rather than marketing claims. The company sources products exclusively from FDA-registered US compounding pharmacies and requires Certificates of Analysis for every product, addressing a documented gap in quality verification within the longevity market.
Longeveron's Phase 2b trial of allogeneic mesenchymal stem cells in older adults with frailty demonstrated safety and measurable improvements in physical performance, including gait speed and functional measures. Results published in Cell Stem Cell validate a therapeutic approach targeting age-related functional decline rather than isolated disease markers.
LifespanningRx introduced a Partner Program enabling non-clinical businesses to offer peptide therapy through clinician oversight, pharmacy fulfillment, and white-label infrastructure. This addresses a gap in scalable delivery of peptide-based interventions within the broader precision medicine ecosystem.
João Pedro de Magalhães and Zhuang Zhuang Han have published a peer-reviewed ethical framework addressing persistent public and scientific concerns about longevity science. The paper provides researchers with evidence-informed arguments to address misconceptions about aging intervention—concerns that have remained largely consistent over two decades despite scientific progress.
A longitudinal study found that 45% of older adults show cognitive improvement over a decade, with positive age-related beliefs associated with better outcomes. This challenges the assumption that cognitive decline is inevitable with age and suggests mindset-dependent mechanisms may influence cognitive trajectory.
Life Time is deploying SpiroFit, a cordless wearable metabolic testing system, across 190 clubs to measure VO2 max and fuel utilization during exercise. The technology generates personalized heart-rate training zones with lab-grade accuracy, enabling members to optimize training intensity and metabolic efficiency.
Perplexity has launched an AI-powered health platform that aggregates fragmented health data from medical records, wearables, and provider systems into a unified dashboard, enabling personalized health insights grounded in individual biomarkers and trends. This addresses a critical infrastructure gap in longevity practice: the ability to contextualize health signals across time and across systems, moving beyond isolated data points toward pattern recognition that supports earlier intervention.
Herbalife's acquisition of Bioniq signals market maturation toward data-driven, individually tailored supplementation based on blood biomarkers and lifestyle data. This shift reflects growing recognition that generic micronutrient approaches fail to address individual metabolic variation and optimization needs.
ARPA-H has awarded $22 million to Linnaeus Therapeutics to test LNS8801, an oral drug designed to preserve physical and cognitive function in aging before decline occurs. The approach represents a shift from treating age-related disease toward maintaining the integrated capacities that sustain independence and resilience.
Regional analysis of 450 European regions over 27 years reveals that life expectancy gains remain sustained in leading regions despite broader stagnation, indicating that longevity plateaus are regional and contextual rather than universal biological limits. Geographic disparities in longevity trajectories suggest that environmental, social, and health system factors continue to drive meaningful variation in human lifespan potential.
Eight Sleep's Pod smart mattress uses continuous biometric monitoring during sleep—tracking heart rate, heart rate variability, and breathing patterns—to shift from reactive treatment to predictive intervention. The company's $1.5 billion valuation reflects a strategic thesis that sleep represents both a high-frequency measurement window and an actionable intervention point for longevity and early disease detection.
A longitudinal study of over 11,000 adults aged 65 and older found that 45% showed improvement in cognitive and/or physical functioning over 12 years, with positive age-related beliefs predicting these gains. This challenges the pervasive assumption that chronological aging inevitably produces decline and demonstrates that improvement remains physiologically possible in later life.
The DAC Egypt Cohort is a longitudinal study designed to identify early biomarkers and risk factors for Alzheimer's disease in an understudied Egyptian population, addressing a critical gap in dementia research outside Western cohorts. Early detection and prevention strategies depend on understanding how disease processes vary across genetic and environmental contexts.
Technogym and Google Cloud are integrating generative AI into fitness platforms to shift from episodic workout protocols toward continuous, anticipatory health management scaled across populations. This partnership pairs four decades of physiological performance data with advanced language models to support adherence—a persistent barrier to preventive health outcomes—while embedding technology into the daily behavioral substrate where health decisions actually occur.
Eli Lilly's $2.75 billion partnership with Insilico Medicine represents a strategic pivot toward AI-driven drug discovery aimed at aging-related pathology beyond current GLP-1 applications. The deal signals that large pharmaceutical companies now view longevity therapeutics as a commercially serious category worthy of substantial investment in discovery infrastructure.
Plasma proteomic analysis of Swiss centenarians identifies a distinct protein signature associated with preserved youthfulness and longevity. This proteomic fingerprint offers a measurable biomarker set for aging trajectories and potential intervention targets.
Lifetime cognitive enrichment from childhood through late life is associated with a 38% reduced dementia risk and delays cognitive decline by 5–7 years. The protective effect accumulates across all life stages, with late-life engagement showing the strongest individual contribution to risk reduction.
Stanford-led THRIVE coalition secured $34.5 million to develop the first FDA-grade Intrinsic Capacity score, a composite measure integrating wearables, blood biomarkers, and functional assessments to predict 20-year health outcomes. This addresses the field's critical gap: the absence of regulatory-grade measurement infrastructure for aging itself, moving beyond disease-specific endpoints toward quantifiable functional decline.
